MMV370
MMV371

Product vision
  • Injectable intra-muscular chemoprotection
MoA
  • Active moiety is atovaquone (selective inhibitor of cytochrome bc1 complex)

Key features
  • Prodrugs of well tolerated marketed prophylactic drug – atovaquone

  • High liver-stage potency

  • Stable formulation – no significant degradation after 1-4 weeks forced conditions

Challenges
  • Potential high cost of goods

Status
  • Candidate selection – July 2018

Next milestone
  • Further formulation work and GLP i.m. safety studies

  • Initiate GLP toxicology program

Previously
  • Calibr-led discovery collaboration

MMV Project Director
  • Dr Andrew Slade